A key health ministry advisory panel will review Bayer Yakuhin’s soluble guanylate cyclase (sGC) stimulator vericiguat for the treatment of chronic heart failure on April 28, two months after putting its decision on hold on whether to recommend its approval.…
To read the full story
Related Article
- MHLW Panel Shelves Decision on Bayer’s Heart Failure Med Vericiguat
February 26, 2021
REGULATORY
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
- Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
- Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
- MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





